Current Report Filing (8-k)
March 23 2017 - 5:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
March 17, 2017
Northwest Biotherapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction
of incorporation or organization)
|
0-35737
(Commission
File Number)
|
94-3306718
(IRS Employer
Identification No.)
|
4800 Montgomery Lane, Suite 800
Bethesda, Maryland 20814
(Address of Principal Executive Offices)
(240) 497-9024
(Registrant’s telephone number, including
area code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions
A.2 below):
|
☐
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 1.01.
|
Entry into a Material Definitive Agreement.
|
As previously reported by Northwest Biotherapeutics,
Inc. (the “Company”), on March 9, 2017, the Company and the holders (the “Holders”) of its 5.00% Convertible
Senior Notes due 2017 (the “Notes”) entered into a Note Repurchase Agreement (the “Repurchase Agreement”).
The Notes were issued pursuant to an (“Indenture”), dated August 19, 2014 (the “Indenture”). On March 17,
2017, the Company executed a first supplemental indenture to the Indenture, providing that a default on the Company’s payment,
performance or other obligations under the Repurchase Agreement in accordance with its terms also is also a default under the Indenture
and that, if such a default occurs and is continuing, the principal of all the Notes and accrued and unpaid interest shall be automatically
due and payable. A copy of the First Supplemental Indenture and the Repurchase Agreement are attached hereto as Exhibits 10.1 and
10.2, respectively, and are incorporated by reference herein.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
Exhibits
.
Exhibit No.
|
Description
|
10.1
|
First Supplemental Indenture, dated March 17, 2017, between Northwest Biotherapeutics, Inc. and The Bank of New York Mellon, as trustee
|
10.2
|
Repurchase Agreement, dated March 8, 2017, between Northwest Biotherapeutics, Inc. and the holders of 5.00% Convertible Senior Notes due 2017
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NORTHWEST BIOTHERAPEUTICS, INC.
|
|
|
|
|
Date: March 23, 2017
|
By:
/s/ Linda Powers
|
|
Name: Linda Powers
Title: Chief Executive Officer
and Chairman
|
EXHIBIT INDEX
Exhibit No.
|
Description
|
10.1
|
First Supplemental Indenture, dated March 17, 2017, between Northwest Biotherapeutics, Inc. and The Bank of New York Mellon, as trustee
|
10.2
|
Repurchase Agreement, dated March 8, 2017, between Northwest Biotherapeutics, Inc. and the holders of 5.00% Convertible Senior Notes due 2017
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Sep 2023 to Sep 2024